Richard P H Huijbregts1, Katherine G Michel1, Zdenek Hel2. 1. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA. 2. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA; Center for AIDS Research, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: zhel@uab.edu.
Abstract
OBJECTIVES: The potential effect of hormonal contraception on HIV-1 acquisition and transmission represents an important public health issue. Several observational studies have suggested an association between the use of hormonal contraception, in particular injectable depot medroxyprogesterone acetate (DMPA), and an increased risk of HIV-1 acquisition and transmission. We and others have previously demonstrated that DMPA acts as a potent inhibitor of innate and adaptive immune mechanisms. The study presented here addresses the immunomodulatory properties of several common progestins with a potential to replace DMPA. STUDY DESIGN: To identify safe alternatives to DMPA, we tested the effect of commonly used progestins on the function of human primary T cells and plasmacytoid dendritic cells (pDCs) obtained from the blood of healthy premenopausal women. RESULTS: Medroxyprogesterone acetate (MPA) inhibited the activation of T cells and pDCs in response to T cell receptor- and Toll-like receptor-mediated activation at physiological concentrations. Etonogestrel exerted a partial suppressive activity at high concentrations. In sharp contrast, norethisterone (NET) and levonorgestrel (LNG) did not exhibit detectable immunosuppressive activity. CONCLUSION: Evidence indicating the immunosuppressive properties of DMPA strongly suggests that DMPA should be discontinued and replaced with other forms of long-term contraception. Since NET and LNG do not exert immunosuppressive properties at physiological concentrations, these progestins should be considered as alternative contraceptives for women at high risk for HIV-1 infection. IMPLICATIONS: The presented data suggest that, at physiological levels, the progestins NET and LNG do not suppress cytokine production by immune cells and should be considered as alternatives to DMPA; however, more in vivo testing is needed to confirm this data.
OBJECTIVES: The potential effect of hormonal contraception on HIV-1 acquisition and transmission represents an important public health issue. Several observational studies have suggested an association between the use of hormonal contraception, in particular injectable depot medroxyprogesterone acetate (DMPA), and an increased risk of HIV-1 acquisition and transmission. We and others have previously demonstrated that DMPA acts as a potent inhibitor of innate and adaptive immune mechanisms. The study presented here addresses the immunomodulatory properties of several common progestins with a potential to replace DMPA. STUDY DESIGN: To identify safe alternatives to DMPA, we tested the effect of commonly used progestins on the function of human primary T cells and plasmacytoid dendritic cells (pDCs) obtained from the blood of healthy premenopausal women. RESULTS:Medroxyprogesterone acetate (MPA) inhibited the activation of T cells and pDCs in response to T cell receptor- and Toll-like receptor-mediated activation at physiological concentrations. Etonogestrel exerted a partial suppressive activity at high concentrations. In sharp contrast, norethisterone (NET) and levonorgestrel (LNG) did not exhibit detectable immunosuppressive activity. CONCLUSION: Evidence indicating the immunosuppressive properties of DMPA strongly suggests that DMPA should be discontinued and replaced with other forms of long-term contraception. Since NET and LNG do not exert immunosuppressive properties at physiological concentrations, these progestins should be considered as alternative contraceptives for women at high risk for HIV-1 infection. IMPLICATIONS: The presented data suggest that, at physiological levels, the progestins NET and LNG do not suppress cytokine production by immune cells and should be considered as alternatives to DMPA; however, more in vivo testing is needed to confirm this data.
Authors: Kristina Abel; Tracy Rourke; Ding Lu; Kristen Bost; Michael B McChesney; Christopher J Miller Journal: J Infect Dis Date: 2004-09-24 Impact factor: 5.226
Authors: Meritxell Genescà; Jun Li; Linda Fritts; Paul Chohan; Kristen Bost; Tracy Rourke; Shelley A Blozis; Michael B McChesney; Christopher J Miller Journal: J Med Primatol Date: 2007-08 Impact factor: 0.667
Authors: Thomas L Cherpes; James L Busch; Brian S Sheridan; Stephen A K Harvey; Robert L Hendricks Journal: J Immunol Date: 2008-07-15 Impact factor: 5.422
Authors: Rodolfo D Vicetti Miguel; Robert L Hendricks; Alfredo J Aguirre; Melissa A Melan; Stephen A K Harvey; Tracy Terry-Allison; Anthony J St Leger; Angus W Thomson; Thomas L Cherpes Journal: J Immunol Date: 2012-08-31 Impact factor: 5.422
Authors: Elizabeth H Byrne; Melis N Anahtar; Kathleen E Cohen; Amber Moodley; Nikita Padavattan; Nasreen Ismail; Brittany A Bowman; Gregory S Olson; Amanda Mabhula; Alasdair Leslie; Thumbi Ndung'u; Bruce D Walker; Musie S Ghebremichael; Krista L Dong; Douglas S Kwon Journal: Lancet Infect Dis Date: 2015-12-24 Impact factor: 25.071
Authors: Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde Journal: Drug Saf Date: 2016-11 Impact factor: 5.606
Authors: Lisa M Noguchi; Barbra A Richardson; Jared M Baeten; Sharon L Hillier; Jennifer E Balkus; Z Mike Chirenje; Katherine Bunge; Gita Ramjee; Gonasagrie Nair; Thesla Palanee-Phillips; Pearl Selepe; Ariane van der Straten; Urvi M Parikh; Kailazarid Gomez; Jeanna M Piper; D Heather Watts; Jeanne M Marrazzo Journal: Lancet HIV Date: 2015-07 Impact factor: 12.767
Authors: Adriana Weinberg; Jeong-Gun Park; Ronald Bosch; Alice Cho; Elizabeth Livingston; Fran Aweeka; Yoninah Cramer; D Heather Watts; Amneris E Luque; Susan E Cohn Journal: J Acquir Immune Defic Syndr Date: 2016-02-01 Impact factor: 3.731